Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Seminars in Cell & Developmental Biology
|
August 9, 2008
Conditional gp130 deficient mouse mutants
Nicolas Fasnacht, Werner Müller
Immunity
|
February 16, 2010
Notch signaling in the immune system
Freddy Radtke, Nicolas Fasnacht, H Robson Macdonald
European Journal of Immunology
|
July 14, 2009
T-cell-specific deletion of gp130 renders the highly susceptible IL-10-deficient mouse resistant to intestinal nematode infection
Nicolas Fasnacht, Marina C Greweling, Mariela Bollati-Fogolín, et al.
Frontiers in Oncology
|
May 19, 2023
Current perspectives on the management of patients with advanced <i>RET</i>-driven thyroid cancer in Europe
Rossella Elisei, Enrique Grande, Michael C Kreissl, et al.
Inflammatory Bowel Diseases
|
December 25, 2010
Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell-derived interleukin-10
Marina C Pils, André Bleich, Immo Prinz, et al.
Future Oncology (London, England)
|
June 6, 2023
Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan
Naoki Fukuda, Yoshinori Tanizawa, Kenichi Nakamura, et al.
European Journal of Immunology
|
November 27, 2009
Monocytes/macrophages and/or neutrophils are the target of IL-10 in the LPS endotoxemia model
Marina C Pils, Fabio Pisano, Nicolas Fasnacht, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 7, 2013
Notch signaling regulates follicular helper T cell differentiation
Floriane Auderset, Steffen Schuster, Nicolas Fasnacht, et al.
The Journal of Experimental Medicine
|
October 15, 2014
Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses
Nicolas Fasnacht, Hsin-Ying Huang, Ute Koch, et al.
Future Oncology (London, England)
|
April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Solange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Seminars in Cell & Developmental Biology
|
August 9, 2008
Conditional gp130 deficient mouse mutants
Nicolas Fasnacht, Werner Müller
Immunity
|
February 16, 2010
Notch signaling in the immune system
Freddy Radtke, Nicolas Fasnacht, H Robson Macdonald
European Journal of Immunology
|
July 14, 2009
T-cell-specific deletion of gp130 renders the highly susceptible IL-10-deficient mouse resistant to intestinal nematode infection
Nicolas Fasnacht, Marina C Greweling, Mariela Bollati-Fogolín, et al.
Frontiers in Oncology
|
May 19, 2023
Current perspectives on the management of patients with advanced <i>RET</i>-driven thyroid cancer in Europe
Rossella Elisei, Enrique Grande, Michael C Kreissl, et al.
Inflammatory Bowel Diseases
|
December 25, 2010
Commensal gut flora reduces susceptibility to experimentally induced colitis via T-cell-derived interleukin-10
Marina C Pils, André Bleich, Immo Prinz, et al.
Future Oncology (London, England)
|
June 6, 2023
Real-world clinical profile, treatment patterns and patient-reported outcomes for thyroid cancer in Japan
Naoki Fukuda, Yoshinori Tanizawa, Kenichi Nakamura, et al.
European Journal of Immunology
|
November 27, 2009
Monocytes/macrophages and/or neutrophils are the target of IL-10 in the LPS endotoxemia model
Marina C Pils, Fabio Pisano, Nicolas Fasnacht, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
August 7, 2013
Notch signaling regulates follicular helper T cell differentiation
Floriane Auderset, Steffen Schuster, Nicolas Fasnacht, et al.
The Journal of Experimental Medicine
|
October 15, 2014
Specific fibroblastic niches in secondary lymphoid organs orchestrate distinct Notch-regulated immune responses
Nicolas Fasnacht, Hsin-Ying Huang, Ute Koch, et al.
Future Oncology (London, England)
|
April 6, 2026
SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in <i>KRAS</i> G12C NSCLC
Solange Peters, Maximilian Hochmair, Kathryn C Arbour, et al.
Page
of 1